Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
   Development
Contracts Management
Review Committees

Funding News

Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) seek patients with blepharospasm for a double-blind, placebo-controlled study of the drug mexiletine.

Eligible patients must have had their last botulinum toxin treatment at least 3 months prior to enrollment in the study, and must have a statement from their primary physician giving medical clearance including an EKG within the past 12 months. Patients with a history of cardiac disease are not eligible. Participants in the study will be asked to stop any medication that may interact with mexiletine.

The study will take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.

For more information, contact Dr. Fiona Molloy at (301) 594-0937 or Dr. Kirsten Zeuner at (301) 402-3499.

---

This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site.  For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.